Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: FDPS

Gene summary for FDPS

Gene summary.

Gene information	Species	Human
	Gene symbol	FDPS
	Gene ID	2224
	Gene name	farnesyl diphosphate synthase
	Gene Alias	FPPS
	Cytomap	1q22
	Gene Type	protein-coding
	GO ID	GO:0006066
	UniProtAcc	P14324

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
2224	FDPS	GSM4909282	Human	Breast	IDC	1.66e-06	3.02e-01	-0.0288
2224	FDPS	GSM4909285	Human	Breast	IDC	8.42e-16	4.65e-01	0.21
2224	FDPS	GSM4909290	Human	Breast	IDC	4.48e-02	3.70e-01	0.2096
2224	FDPS	GSM4909294	Human	Breast	IDC	4.78e-02	-1.13e-01	0.2022
2224	FDPS	GSM4909296	Human	Breast	IDC	1.72e-07	-6.94e-02	0.1524
2224	FDPS	GSM4909297	Human	Breast	IDC	6.75e-10	-2.76e-01	0.1517
2224	FDPS	GSM4909301	Human	Breast	IDC	1.97e-18	4.93e-01	0.1577
2224	FDPS	GSM4909311	Human	Breast	IDC	6.61e-28	-3.74e-01	0.1534
2224	FDPS	GSM4909312	Human	Breast	IDC	3.43e-10	-8.48e-02	0.1552
2224	FDPS	GSM4909319	Human	Breast	IDC	3.15e-34	-2.83e-01	0.1563
2224	FDPS	GSM4909321	Human	Breast	IDC	4.32e-11	-6.32e-02	0.1559
2224	FDPS	brca1	Human	Breast	Precancer	3.23e-23	5.95e-01	-0.0338
2224	FDPS	brca2	Human	Breast	Precancer	1.07e-24	5.94e-01	-0.024
2224	FDPS	M2	Human	Breast	IDC	7.41e-03	3.61e-01	0.21
2224	FDPS	NCCBC14	Human	Breast	DCIS	3.65e-05	1.20e-01	0.2021
2224	FDPS	NCCBC5	Human	Breast	DCIS	2.07e-04	-1.45e-01	0.2046
2224	FDPS	P1	Human	Breast	IDC	1.05e-14	-3.10e-01	0.1527
2224	FDPS	P2	Human	Breast	IDC	2.81e-06	4.22e-01	0.21
2224	FDPS	DCIS2	Human	Breast	DCIS	9.59e-56	-8.19e-02	0.0085
2224	FDPS	CA_HPV_1	Human	Cervix	CC	5.17e-05	-2.43e-01	0.0264

Page: 1 2 3 4 5 6 7 8 9 10

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00066944	Breast	IDC	steroid biosynthetic process	25/1434	173/18723	1.56e-03	1.56e-02	25
GO:000669411	Breast	DCIS	steroid biosynthetic process	23/1390	173/18723	4.63e-03	3.52e-02	23
GO:0006066	Colorectum	AD	alcohol metabolic process	106/3918	353/18723	3.02e-05	5.57e-04	106
GO:0006644	Colorectum	AD	phospholipid metabolic process	101/3918	383/18723	5.80e-03	3.67e-02	101
GO:0008202	Colorectum	AD	steroid metabolic process	85/3918	319/18723	8.07e-03	4.75e-02	85
GO:00060661	Colorectum	SER	alcohol metabolic process	79/2897	353/18723	3.50e-04	5.50e-03	79
GO:00066441	Colorectum	SER	phospholipid metabolic process	79/2897	383/18723	3.94e-03	3.24e-02	79
GO:0008654	Colorectum	FAP	phospholipid biosynthetic process	54/2622	253/18723	8.88e-04	9.08e-03	54
GO:00066442	Colorectum	FAP	phospholipid metabolic process	74/2622	383/18723	2.24e-03	1.83e-02	74
GO:00060663	Colorectum	FAP	alcohol metabolic process	69/2622	353/18723	2.29e-03	1.85e-02	69
GO:00086541	Colorectum	CRC	phospholipid biosynthetic process	49/2078	253/18723	7.07e-05	1.51e-03	49
GO:00066443	Colorectum	CRC	phospholipid metabolic process	65/2078	383/18723	3.21e-04	4.95e-03	65
GO:00060664	Colorectum	CRC	alcohol metabolic process	57/2078	353/18723	2.37e-03	2.27e-02	57
GO:00086544	Esophagus	ESCC	phospholipid biosynthetic process	162/8552	253/18723	2.59e-09	5.73e-08	162
GO:00066446	Esophagus	ESCC	phospholipid metabolic process	218/8552	383/18723	5.37e-06	5.59e-05	218
GO:00060668	Esophagus	ESCC	alcohol metabolic process	202/8552	353/18723	7.32e-06	7.26e-05	202
GO:00161263	Esophagus	ESCC	sterol biosynthetic process	46/8552	64/18723	1.91e-05	1.67e-04	46
GO:00066953	Esophagus	ESCC	cholesterol biosynthetic process	41/8552	57/18723	5.25e-05	4.06e-04	41
GO:19026533	Esophagus	ESCC	secondary alcohol biosynthetic process	41/8552	57/18723	5.25e-05	4.06e-04	41
GO:19026524	Esophagus	ESCC	secondary alcohol metabolic process	87/8552	147/18723	6.58e-04	3.50e-03	87

Page: 1 2 3 4 5

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0516618	Breast	Precancer	Human T-cell leukemia virus 1 infection	33/684	222/8465	4.29e-04	3.31e-03	2.53e-03	33
hsa0516619	Breast	Precancer	Human T-cell leukemia virus 1 infection	33/684	222/8465	4.29e-04	3.31e-03	2.53e-03	33
hsa0516624	Breast	IDC	Human T-cell leukemia virus 1 infection	40/867	222/8465	2.52e-04	2.21e-03	1.66e-03	40
hsa0516634	Breast	IDC	Human T-cell leukemia virus 1 infection	40/867	222/8465	2.52e-04	2.21e-03	1.66e-03	40
hsa0516642	Breast	DCIS	Human T-cell leukemia virus 1 infection	41/846	222/8465	7.03e-05	6.88e-04	5.07e-04	41
hsa0516652	Breast	DCIS	Human T-cell leukemia virus 1 infection	41/846	222/8465	7.03e-05	6.88e-04	5.07e-04	41
hsa0516620	Cervix	CC	Human T-cell leukemia virus 1 infection	61/1267	222/8465	8.13e-07	7.98e-06	4.72e-06	61
hsa0516414	Cervix	CC	Influenza A	43/1267	171/8465	3.03e-04	1.64e-03	9.68e-04	43
hsa05166110	Cervix	CC	Human T-cell leukemia virus 1 infection	61/1267	222/8465	8.13e-07	7.98e-06	4.72e-06	61
hsa0516415	Cervix	CC	Influenza A	43/1267	171/8465	3.03e-04	1.64e-03	9.68e-04	43
hsa05166	Colorectum	AD	Human T-cell leukemia virus 1 infection	72/2092	222/8465	5.24e-03	2.44e-02	1.55e-02	72
hsa051661	Colorectum	AD	Human T-cell leukemia virus 1 infection	72/2092	222/8465	5.24e-03	2.44e-02	1.55e-02	72
hsa0516626	Endometrium	AEH	Human T-cell leukemia virus 1 infection	50/1197	222/8465	4.30e-04	3.11e-03	2.27e-03	50
hsa05166111	Endometrium	AEH	Human T-cell leukemia virus 1 infection	50/1197	222/8465	4.30e-04	3.11e-03	2.27e-03	50
hsa0516627	Endometrium	EEC	Human T-cell leukemia virus 1 infection	52/1237	222/8465	2.73e-04	2.36e-03	1.76e-03	52
hsa0516636	Endometrium	EEC	Human T-cell leukemia virus 1 infection	52/1237	222/8465	2.73e-04	2.36e-03	1.76e-03	52
hsa0516420	Esophagus	HGIN	Influenza A	42/1383	171/8465	3.41e-03	2.54e-02	2.02e-02	42
hsa0516639	Esophagus	HGIN	Human T-cell leukemia virus 1 infection	51/1383	222/8465	5.84e-03	4.05e-02	3.22e-02	51
hsa05164110	Esophagus	HGIN	Influenza A	42/1383	171/8465	3.41e-03	2.54e-02	2.02e-02	42
hsa05166114	Esophagus	HGIN	Human T-cell leukemia virus 1 infection	51/1383	222/8465	5.84e-03	4.05e-02	3.22e-02	51

Page: 1 2 3

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

FDPS

SNV

Missense_Mutation

c.1036C>G

p.Pro346Ala

p.P346A

P14324

protein_coding

tolerated(0.09)

benign(0.006)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

FDPS

SNV

Missense_Mutation

c.458C>A

p.Thr153Asn

p.T153N

P14324

protein_coding

deleterious(0.01)

benign(0.184)

TCGA-E2-A10C-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

FDPS

SNV

Missense_Mutation

novel

c.671N>T

p.Glu224Val

p.E224V

P14324

protein_coding

deleterious(0.01)

possibly_damaging(0.736)

TCGA-PE-A5DD-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

FDPS

SNV

Missense_Mutation

novel

c.1150N>A

p.Glu384Lys

p.E384K

P14324

protein_coding

deleterious(0.01)

possibly_damaging(0.708)

TCGA-PE-A5DD-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

FDPS

SNV

Missense_Mutation

c.1036C>G

p.Pro346Ala

p.P346A

P14324

protein_coding

tolerated(0.09)

benign(0.006)

TCGA-PE-A5DE-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

taxotere

FDPS

insertion

In_Frame_Ins

novel

c.672_673insTCTACCCTGACCTTGCTT

p.Glu224_Leu225insSerThrLeuThrLeuLeu

p.E224_L225insSTLTLL

P14324

protein_coding

TCGA-PE-A5DD-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

FDPS

SNV

Missense_Mutation

c.294N>C

p.Glu98Asp

p.E98D

P14324

protein_coding

tolerated(0.63)

benign(0)

TCGA-DS-A0VM-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

FDPS

SNV

Missense_Mutation

c.816N>G

p.Phe272Leu

p.F272L

P14324

protein_coding

deleterious(0.02)

benign(0.354)

TCGA-LP-A5U2-01

Cervix

cervical & endocervical cancer

Female

<65

III/IV

Unknown

FDPS

SNV

Missense_Mutation

c.556N>G

p.Gln186Glu

p.Q186E

P14324

protein_coding

deleterious(0.02)

benign(0.011)

TCGA-Q1-A5R3-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

FDPS

SNV

Missense_Mutation

c.1180C>G

p.Leu394Val

p.L394V

P14324

protein_coding

deleterious(0.02)

benign(0.326)

TCGA-Q1-A73O-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

Page: 1 2 3 4 5 6

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
2224	FDPS	DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE		IBANDRONATE	IBANDRONIC ACID
2224	FDPS	DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE	inhibitor	CHEMBL924	ZOLEDRONIC ACID
2224	FDPS	DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE	inhibitor	178103833
2224	FDPS	DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE		Bisphosphonates		18687167,24311107,21151198
2224	FDPS	DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE		Zoledronate	ZOLEDRONIC ACID
2224	FDPS	DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE	inhibitor	135651495
2224	FDPS	DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE	inhibitor	135650701
2224	FDPS	DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE	inhibitor	135650699
2224	FDPS	DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE	inhibitor	135650697
2224	FDPS	DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE		MINODRONATE

Page: 1 2 3 4 5 6